Prof. Özkan Kanat is a physician and pharmacologist with a PhD in Pharmacology from Uludağ University (2013). He combines clinical expertise and research experience to improve patient care and therapeutic outcomes. Since 2019 he has been affiliated with Acıbadem Health Group, where he applies his knowledge in pharmacology to clinical practice, treatment planning, and interdisciplinary collaboration. He is committed to evidence-based medicine, ongoing professional development, and translating research findings into practical solutions for patients and healthcare teams.
Education
- 2013 Uludag University / Pharmacology / PhD
- 2001 Uludag University Faculty of Medicine Medical Oncology
- 2000 Uludag University Faculty of Medicine Internal Medicine
- 1995 Ondokuzmayıs University Faculty of Medicine
Experience
- 2019 Acibadem Health Group
- 1995 – 2019 Uludag University Faculty of Medicine Department of Internal Medicine / Division of Medical Oncology
- 2012 Vall d”Hebron Institute of Oncology Gastrointestinal and Phase I units / Barcelona (with Prof. Joseph Tabernero)
- 2011 Fox Chase Cancer Center Philadelphia Externship Organization
- 2011 The University of North Carolina at Chapel Hill Cancer Hospital / Gastrointestinal Cancer Unit (with Prof. Bert O?Neil and Prof. Richard Goldberg)
- 2011 Memorial Sloan Kettering Cancer Center / Gastrointestinal Cancer Unit (with Prof. Nancy Kemeny) / New York, United States of America
Publications
- Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
World J Clin Cases. 2018 Oct 6;6(11):418-425. doi: 10.12998/wjcc.v6.i11.418. Review. Kanat O, Ertas H, Caner B. - Shattering the castle walls: Anti-stromal therapy for pancreatic cancer
World J Gastrointest Oncol. 2018 Aug 15;10(8):202-210. doi: 10.4251/wjgo.v10.i8.202. Review. Kanat O, Ertas H. - Platinum-induced neurotoxicity: A review of possible mechanisms
World J Clin Oncol. 2017 Aug 10;8(4):329-335. doi: 10.5306/wjco.v8.i4.329. Review. Kanat O, Ertas H, Caner B. - Immunohistochemical expression of CDX2, CK7, HER2 and HER4 in periampullary adenocarcinoma : implications for clinicopathology and patient outcomes
Acta Gastroenterol Belg. 2017 Jan-Mar;80(1):31-37. Uğraş N, Yerci Ö, Özgün G, Deligönül A, Dündar HZ, Sarkut P, Kanat Ö. - Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer
J BUON. 2016 May-Jun;21(3):564-9 Deligonul A, Evrensel T, Avci N, Ugras N, Ture M, Cubukcu E, Hartavi M, Fatih Olmez O, Kurt E, Tolunay S, Kanat O, Manavoglu O. - Current treatment options for patients with initially unresectable isolated colorectal liver metastases
World J Clin Oncol. 2016 Feb 10;7(1):9-14. doi: 10.5306/wjco.v7.i1.9. Kanat O. - Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients
Asian Pac J Cancer Prev. 2016;17(3):1175-9. Gorukmez O, Yakut T, Gorukmez O, Sag SO, Karkucak M, Kanat O. - Targeted therapy for advanced gastric cancer: A review of current status and future prospects
World J Gastrointest Oncol. 2015 Dec 15;7(12):401-10. doi: 10.4251/wjgo.v7.i12.401. Review. Kanat O, O”Neil B, Shahda S. - linical significance of adiponectin expression in colon cancer patients
J Cancer Res Ther. 2014 Apr-Jun;10(2):347-53. doi: 10.4103/0973-1482.136634. Canhoroz M, Kanat O, Saraydaroglu O, Buluc E, Avci N, Cubukcu E, Olmez OF, Manavoglu O. - Lack of prognostic significance of adiponectin immunohistochemical expression in patients with triple-negative breast cancer
Contemp Oncol (Pozn). 2014;18(1):34-8. doi: 10.5114/wo.2014.40454. Epub 2014 Feb 28. Cubukcu E, Olmez OF, Kanat O, Kabul S, Canhoroz M, Avci N, Hartavi M, Deligonul A, Cubukçu S, Manavoglu O.
